Tag: Boston Scientific

Boston Scientific announces schedule of presentations at TCT 2019

Boston Scientific has announced the key data that will be presented at the Transcatheter Cardiovascular Therapeutics conference (TCT 2019; 25–29 September, San Francisco, USA). Data...

Novel repositionable TAVI valve has acceptable early clinical outcomes

A new study indicates that the Meridian transcatheter aortic valve implantation (TAVI) valve (HLT) is associated with a 30-day mortality rate of 8% and...

New trial to compare Watchman FLX to direct oral anticoagulants

The OPTION trial is to compare the compare safety and effectiveness of the next-generation Watchman FLX left atrial appendage closure platform with first-line oral...

Boston Scientific initiates trial comparing left atrial appendage closure to direct...

According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial...

Lotus Edge becomes third TAVI device on US market

Boston Scientific has received US FDA approval for its Lotus Edge transcatheter aortic valve implantation (TAVI) system. It is approved for patients with severe...

CE mark for Watchman FLX left atrial appendage closure device

Boston Scientific announced it has received CE mark and initiated a limited market release of the next generation Watchman FLX left atrial appendage closure...

Boston Scientific, Edwards Lifesciences agree to global litigation settlement

Boston Scientific and Edwards Lifesciences today announced that the companies have reached an agreement to settle all outstanding patent disputes between the companies in...

Boston Scientific exercises option to acquire Millipede

Boston Scientific has exercised its option to acquire the remaining shares of Millipede, upon its recent successful completion of a first-in-human clinical study. The...

US District Court for the District of Delaware rules that Sapien...

A jury in the US District Court for the District of Delaware determined that the Boston Scientific US patent 8,992,608 is valid and that...

ADVERTORIAL: Unique design and features of the ACURATE neo (TM) enable...

This content is only for readers outside of the US as it discusses a device that is not FDA approved. Results from the SAVI-TF Registry1,...

PCR LV 2018: Favourable outcomes for next-generation Acurate neo2 TAVI system

A new study evaluating the safety and performance of the Acurate neo2 (Boston Scientific) transcatheter aortic valve implantation (TAVI) system demonstrated a high procedural...

Boston Scientific to buy cerebral protection system company

Boston Scientific has signed an agreement to acquire Claret Medical, which developed and commercialised the Sentinel cerebral embolic protection system. The device is used...

EuroPCR 2018: Boston Scientific outlines its key presentations

Boston Scientific Corporation has revealed its schedule of key presentations—including two late-breaking clinical trials—that will be featured at the 2018 EuroPCR (22–25 May, Paris,...

Boston Scientific successfully opposes Edwards Lifesciences Corporation’s European patent EP 2,399,550...

According to a press release, Boston Scientific has, along with several other opponents, successfully opposed Edwards Lifesciences Corporation's European patent EP 2,399,550 (550) in...

UK Court of Appeal dismisses Edwards Lifesciences’ appeal against Sapien 3...

Acurate neo Boston Scientific has announced the UK Court of Appeal  dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’...

Short-term DAPT is feasible for patients undergoing percutaneous LAA closure

Felix Weise (Cardioangiologisches Centrum Bethanien, Frankfurt, Germany) and others report in EuroIntervention that a strategy of six weeks’ duration of dual antiplatelet therapy (DAPT)...

Boston Scientific enters into an acquisition option agreement with Millipede

Boston Scientific has closed an investment and entered into an acquisition option agreement with Millipede, which has developed the “IRIS” transcatheter annuloplasty ring system...

Boston Scientific pushes back plans for commercialisation of Lotus Edge TAVI...

Boston Scientific has announced a delay to the previously communicated timelines for the commercialisation of its Lotus Edge transcatheter aortic valve implantation (TAVI) device...

TCT 2017: Vivek Reddy on the final outcomes of PREVAIL and...

Boston Scientific has announced the final five-year outcomes data from the PREVAIL study during a late-breaking clinical trial session at this year’s Transcatheter Cardiovascular Therapeutics (TCT;...

TCT 2017: No role for bare metal stents to reduce duration...

Olivier Varenne (Hôpital Cochin, Assistance Publique—Hôpitaux De Paris, Paris, France) reported that the strategy of using bare metal stents to enable a shorter duration...

TCT 2017: Boston Scientific reveals presentations at conference

Boston Scientific has announced key data will be presented at next week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA). For example,...

PCR LV 2017: Refining implantation technique and device iterations may improve...

New data from REPRISE III indicate that keeping the bottom of the frame at annular level while implanting and targeting a final depth of...

ESC 2017: Best-practice PCI outperforms conventional PCI in patients with de...

The SYNTAX II study has found that percutaneous coronary intervention (PCI) using state-of-the-art techniques—including physiological assessment and a new-generation drug-eluting stent—significantly reduces the rate...

EuroPCR 2017: Lotus TAVI device has superior efficacy to CoreValve at...

Data from the REPRISE III trial indicate that the Lotus transcatheter aortic valve implantation (TAVI) device (Boston Scientific) is associated with a significantly lower...

SCAI 2017: New data from PLATINUM Diversity study provide further insight...

New analyses from the PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can adversely affect stent-related...

Boston Scientific closes Symetis acquisition

Boston Scientific Corporation has announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on transcatheter aortic valve...

ADVERT: SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System Drug Eluting stent technology with durable polymer has shown encouraging efficacy compared to bare metal stents, significantly reducing restenosis...

UK Patents Court makes initial decision on Edwards Sapien 3 and...

The Patents Court in the UK has determined that one of Boston Scientific’s patents related to outer seals for transcatheter heart valves that was...

Corindus Vascular Robotics announces private placement for US$45 million

Corindus Vascular Robotics has entered into a Securities Purchase Agreement pursuant to which it will issue and sell an aggregate of 67,941,346 shares of...

Locking mechanism problems prompt Boston Scientific to recall all ranges of...

According to Reuters, Boston Scientific is recalling all ranges of its transcatheter aortic valve implantation (TAVI) device Lotus. The news agency reports that the...

Boston Scientific closes acquisition of certain Neovasc assets

Boston Scientific Corporation has closed its acquisition of certain manufacturing assets and capabilities of the Neovasc advanced biological tissue business. With the completion of...

Boston Scientific to acquire Neovasc biological tissue capabilities

Boston Scientific has agreed to acquire certain manufacturing assets and capabilities of the Neovasc advanced biological tissue business, as well as a 15% equity...

TCT 2016: Women and minorities have a significantly higher risk...

Data from the PLATINUM DIVERSITY trial, which was presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington DC, USA), indicates...

TCT 2016: Boston Scientific announces scheduled presentations

Boston Scientific has announced key data that will be presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA)....

Ian Meredith to become global chief medical officer of Boston Scientific

Ian Meredith, currently professor of Medicine and Cardiology for Monash University, Director of MonashHeart and Monash Health and as executive director of the Monash...

Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent

The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery...

PCRLV 2016: Next-generation of Lotus TAVI receives CE mark

Coinciding with PCR London Valves (18-20 September, London, UK), Boston Scientific has announced it has received the CE mark for its Lotus Edge transcatheter...

Boston Scientific issues urgent recall of Lotus systems manufactured prior to...

Boston Scientific has sent a letter to its customers notifying them that it is implementing a “voluntary Field Safety Corrective Action (FSCA)” for its...